Metagenomi initiated with an Outperform at TD Cowen

TD Cowen initiated coverage of Metagenomi with an Outperform rating and no price target. The analyst says the company has created a large, diverse gene editing toolbox positioned to correct any type of genetic mutation. The firm sees the breadth of Metagenomi’s technologies as differentiated and believes its lead hemophilia A program has the potential to address shortcomings with available therapies.